Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

CMMB Chemomab Therapeutics Ltd

0,8202

-0,0398 (-4,63%)

Dernière mise à jour : 18:47:30

Retardé de 15 minutes

Biotech Shares Massively Bid Up Before Opening Bell

A Biotech stock based out of Tel Aviv has found tremendous success so far during Tuesday’s session after it was announced that the Patent Offices in Brazil and Israel have...

To read the full story on AllPennyStocks.com, click here.

Chemomab Therapeutics (NASDAQ:CMMB)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024

Plus de graphiques de la Bourse Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024

Plus de graphiques de la Bourse Chemomab Therapeutics

Actualités Chemomab Therapeutics Ltd

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
Vendredi 17 Mai 2024 ( il y a 4 jours) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 9 Mai 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Jeudi 9 Mai 2024 ( il y a 2 semaines) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercredi 8 Mai 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Mercredi 8 Mai 2024 ( il y a 2 semaines) • GlobeNewswire Inc.

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Jeudi 2 Mai 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Mercredi 24 Avril 2024 ( il y a 4 semaines) • GlobeNewswire Inc.

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Jeudi 18 Avril 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Mardi 2 Avril 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Lundi 25 Mars 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 7 Mars 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
Jeudi 7 Mars 2024 ( il y a 2 mois) • PR Newswire (US)

Plus d'articles sur Chemomab Therapeutics Ltd

Societe Generale

Cie de SaintGobain

JP Morgan Chase

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales